Drug Profile

AGT 115

Alternative Names: AGT-115; HIRMAb-EPO fusion protein

Latest Information Update: 08 Jun 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ArmaGen Technologies
Class Antiparkinsonians; Erythropoietins; Immunoglobulin fusion proteins; Neuroprotectants; Vascular disorder therapies
Mechanism of Action Reactive oxygen species inhibitors; Tyrosine hydroxylase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

08 Jun 2021 AGT 115 is still in preclinical trials in Parkinson's disease in USA (IV) (ArmaGen Technologies pipeline, June 2021)
08 Jun 2021 AGT 115 is still in preclinical trials in Stroke in USA (IV) (ArmaGen Technologies pipeline, June 2021)
28 Apr 2021 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (IV, Injection)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com